Proton-pump inhibitors are the treatment of choice in acid-related disease

被引:2
|
作者
Brunner, G [1 ]
机构
[1] UNIV HANNOVER, SCH MED, DEPT MED, DIV GASTROENTEROL & HEPATOL, D-30167 HANNOVER, GERMANY
关键词
proton-pump inhibitors; H-2-receptor antagonists; acid-related disease;
D O I
10.1097/00042737-199610001-00003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Increasing intragastric pH: Effective treatment of acid-related disease requires an increase in intragastric pH. The two principal pharmacological methods of attaining this goal are (1) using histamine (H-2)-receptor antagonists to block H-2-receptors on the parietal cell and (2) using proton-pump inhibitors to stop acid production acid at its source. H-2-receptor antagonists: H-2-receptor antagonists bind loosely and non-covalently to receptors on the parietal cell. They represented a great advance when they first appeared, bringing relief to many patients and improving the standard of care, with fewer operations and hospitalizations and a generally improved quality of life. However, many patients do not respond to these drugs, either because of the nature of the disease or because of resistance to the agent. Proton-pump inhibitors: Proton-pump inhibitors represent an advance in the therapy of acid-related disease because they inhibit all acid production, no matter what the source of the stimulus, by binding covalently to the proton pump. Compared with H-2-receptor antagonists, the effect of proton-pump inhibition is longer-lasting, faster-acting, and more effective, curing 99% of patients resistant to H-2-receptor antagonist therapy. These properties make proton-pump inhibitors the treatment of choice for acid-related diseases.
引用
收藏
页码:S9 / S13
页数:5
相关论文
共 50 条
  • [41] Proton-pump inhibitors: understanding the complications and risks
    Malfertheiner, Peter
    Kandulski, Arne
    Venerito, Marino
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2017, 14 (12) : 697 - 710
  • [42] Proton-pump inhibitors: understanding the complications and risks
    Peter Malfertheiner
    Arne Kandulski
    Marino Venerito
    Nature Reviews Gastroenterology & Hepatology, 2017, 14 : 697 - 710
  • [43] Appropriate Use and Stewardship of Proton-Pump Inhibitors
    Ren, Dylan
    Gurney, Erin
    Hornecker, Jaime R.
    US PHARMACIST, 2019, 44 (12) : 25 - 31
  • [44] Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors
    Janett, Simone
    Camozzi, Pietro
    Peeters, Gabriella G. A. M.
    Lava, Sebastiano A. G.
    Simonetti, Giacomo D.
    Simonetti, Barbara Goeggel
    Bianchetti, Mario G.
    Milani, Gregorio P.
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2015, 2015
  • [45] Proton-pump inhibitors, tooth extraction, and dementia
    Kawada, Tomoyuki
    ORAL DISEASES, 2024, 30 (02) : 794 - 795
  • [46] Aspirin and proton-pump inhibitors: interpreting the interplay
    Vaduganathan, Muthiah
    Bhatt, Deepak L.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (01) : 20 - 22
  • [47] Hypomagnesemia Induced by Several Proton-Pump Inhibitors
    Broeren, Maarten A. C.
    Geerdink, Engelien A. M.
    Vader, Huib L.
    Bake, A. Warmold L. van den Wall
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (10) : 755 - 756
  • [48] Another bad break for proton-pump inhibitors?
    Laura E. Targownik
    Nature Reviews Rheumatology, 2009, 5 : 478 - 480
  • [49] Novel methods of using proton-pump inhibitors
    Vakil, N
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2002, 31 (04) : S85 - +
  • [50] Another bad break for proton-pump inhibitors?
    Targownik, Laura E.
    NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (09) : 478 - 480